

CUMULATIVE INDEX 1995

Volume 13

January	GENODERMATOSES WITH MALIGNANT POTENTIAL, pages 1-243
April	COSMETIC DERMATOLOGY, pages 245-503
July	DERMATOEPIDEMIOLOGY, pages 505-716
October	PSORIASIS, pages 717-955

Note: Page numbers of article titles are in **boldface** type.

- Acitretin. See *Systemic retinoids*.
- Acne, active, dermabrasion for, 315
- Acne scarring, dermabrasion for, 313-315
- Acquired melanocytic nevi, **595-603**
analytic studies of, in adults, 596-599
in children, 599, 601
clinical definition and enumeration of, 596
- Acrodermatitis continua, management of, 775
- Actinic keratosis, interferons for, 703-704
- Acyclovir, for herpes simplex infection, in HIV infection, 232-233
for varicella-zoster virus, in HIV infection, 233
- Adenocarcinoma, gastrointestinal, in Peutz-Jeghers syndrome, 130
of colon, in Gardner's syndrome, 54
- Adenoma sebaceum, in tuberous sclerosis complex, 152
- Adenomas, pituitary, in Carney complex, 24
- Adenomatous colon polyps, in Gardner's syndrome, 54, 55
- African iron overload, malignancies associated with, 59-60
- Aging face, etiology of, 245
photoaging in, 245-247
cellular and molecular aspects of, 246-247
classification of, 247
clinical aspects of, 245-246
histology of, 247
treatment of, **245-261**
alpha-hydroxy acids in, 248-249
chemical peels in. See *Chemical peels*.
cryopeels in, 253
dermabrasion in. See *Dermabrasion*.
moisturizers in, 248
soft tissue augmentation in. See *Microlipoinjection*.
sunscreens in, 248
topical tretinoin in, 249, 251
- AIDS, Kaposi's sarcoma in. See *Kaposi's sarcoma*.
- Alcohol, role of, in psoriasis, 639-641, 718, 796
- Alexandrite lasers, in cosmetic dermatology, 455
- Allergens, role of, in atopic dermatitis, 655
- Allergic reactions, blepharoplasty and, 421
- Alpha-hydroxy acids, for aging face, 248-249
- Amenorrhea, systemic glucocorticosteroids and, 934-935
- Amyloidosis, lichen, in multiple endocrine neoplasia 2/2A, 92
- Analgesia, in tumescent liposuction, 337
- Anesthesia, for chemical peels, 269
for dermabrasion, 320
for lower lid blepharoplasty, 409
for tumescent liposuction, 329-330
for upper lid blepharoplasty, 400, 402
- Angioedema, drug-induced, 685-686
- Angiofibromas, facial, in tuberous sclerosis complex, 152
- Angiomyolipomas, renal, in tuberous sclerosis complex, 154, 156
- Angiotensin-converting enzyme inhibitors, and angioedema, 686
- Ankylosing spondylitis, vs. psoriatic arthritis, 788
- Anthralin, for psoriasis, 822-829
clinical uses of, 824-829
modification of Ingram regimen, 824-825
short-contact regimens, 825-827
with phototherapy, 827-829, 869
formulations and pharmacology of, 822-823
mechanism of action of, 823
side effects of, 823-824
- Antibiotics, for Lyme disease, 539-540
for psoriasis, **909-913**
choice of drug in, 911-913
historical aspects of, 909-910
laboratory results in, 910-911
pretherapy evaluation for, 910
prophylactic, in tumescent liposuction, 337
- Antibody-containing blood products, receipt of, as contraindication to measles vaccination, 557-558
- Antigen-presenting cells, in psoriasis, 739-740
- Antimalarials, for porphyrias, 141
- Aphthous stomatitis, in HIV infection, 237
- Argon lasers, in cosmetic dermatology, 449
- Argon-pumped tunable dye lasers, in cosmetic dermatology, 450
- Arthritis, psoriatic. See *Psoriatic arthritis*.
with psoriasis, 725
- Arytenoid ethyl ester. See *Systemic retinoids*.
- Ash leaf spots, in tuberous sclerosis complex, 151-152
- Astrocytomas, giant cell, in tuberous sclerosis complex, 156, 160
- Ataxia-telangiectasia, **1-6**
malignancies associated with, 2

- Ataxia-telangiectasia (*Continued*)
 mucocutaneous stigmata of, 1-2
 noncutaneous features of, 2
 work-up for, 2-5
- Atherosclerosis, systemic glucocorticosteroids and, 934
- Atopic dermatitis, 649-657
 definition of, 649-653
 applying hospital criteria in population setting, 650-651
 categoric or dimensional, 650
 diagnostic criteria for, 651
 statistical, prognostic, operational, or clinical, 649-650
 UK working party refinement of, 651-653
 descriptive epidemiology of, 653-656
 environmental factors in, 654-655
 fetal and infant influences in, 654
 genetics in, 654
 natural history in, 654
 prevalence and morbidity in, 653-654
 in Wiskott-Aldrich syndrome, 68
 interferons for, 702
 prevention of, 655-656
- Autologous collagen, microlipoinjection of. See *Microlipoinjection*.
- Autologous fat, microlipoinjection of. See *Microlipoinjection*.
- Axillary freckling, in neurofibromatosis, 106-107
- Azidothymidine, with interferons, for AIDS-related Kaposi's sarcoma, 701
- Bacillary angiomatosis, in HIV infection, 231-232
- Bacille Calmette-Guérin vaccination, against leprosy, 533
- Bacterial infections, in chemical peels, 310
 in HIV infection. See *HIV infection*.
 in Wiskott-Aldrich syndrome, 68
- Baker-Gordon solution, for chemical peels, 269-270
- Basal cell carcinoma, in nevroid basal cell carcinoma syndrome, 114
 increased risk of, therapy for psoriasis and, 860
 interferons for, 702-703
- Bazex syndrome, basal cell carcinoma in, 120-121
- Beckwith-Wiedemann syndrome, 211-214
 malignancies associated with, 214
 mucocutaneous stigmata of, 212-214
 noncutaneous features of, 214
- Behçet's disease, interferons for, 706
- Benign pigmented nevi, and melanoma, screening for, 629
- Benoxaprofen, for psoriasis, 917
- Betamethasone dipropionate, for psoriasis, 810
- Biologic response modifiers, for psoriasis, 745
- Biopsies, liver, to monitor methotrexate therapy, for psoriasis, 880
- Birt-Hogg-Dube syndrome, malignancies associated with, 214-216
- Blepharoplasty, 389-430
 indications for, 389
 long-term results of, 427, 430
 lower lid measurements for, 400
 lower lid skin and muscle technique for, 417-418
 lower lid skin flap technique for, 409, 416-417
 patient consultation for, 389
 patient evaluation for, 389-390
 patient examination for, 390-395
 laboratory tests in, 395
 ophthalmic, 394-395
 photographs in, 395-399
 preoperative, 390, 392-394
 postoperative care for, 418
 postoperative follow-up examination for, 418-427
 preoperative instructions and release for, 399
 preoperative marking for, 399-400
 preoperative preparation for, 399
 transconjunctival lower lid procedure in, 409
 upper lid measurements for, 400
 upper lid operative procedure in, 400, 402-409
- Blindness, blepharoplasty and, 423, 427
- Bloch-Sulzberger syndrome, malignancies associated with, 219-220
- Blood cell effects, of systemic glucocorticosteroids, 935
- Blood transfusions, and leishmaniasis, 516-517
- Bloom's syndrome, 7-18
 clinical features of, 8-11
 explanation for, 13-14
 diagnosis of, 16
 etiology of, 14-16
 genetics in, 14-15
 genomic instability in, 15-16
 malignancies associated with, 12-13
 management of, 16-18
 non-sun-sensitive lesions in, 12
 sun-sensitive facial lesions in, 11-12
- Blue nevi, in Carney complex, 20
- Bone marrow transplantation, for dyskeratosis congenita, 37
 for Fanconi anemia, 46
- Borrelia burgdorferi*. See *Lyme disease*.
- Bowenoid papulosis, human papillomavirus in, 568, 569
 interferons for, 706
- Bowing, lateral, blepharoplasty and, 422
- Breast lesions, in Cowden syndrome, 28
- Burns, role of, in skin cancer, 591
- Café-au-lait macules, in neurofibromatosis, 105-106
- Calcipotriol, for psoriasis, 743, 835-841, 916
 in HIV infection, 236
 indications for, 838
 mechanism of action of, 835-837
 safety of, 837-838
 side effects of, 837
 with phototherapy, 836-837, 848, 918
 for pustular psoriasis, 763
- Camouflage therapy, in cosmetic dermatology, 467-472
 application of, 464
 color blending in, 471
 color correction in, 471
 duplication of skin imperfections in, 471-472
 indications for, 467-468
 limitations of, 471
 materials for, 468, 471
 patient evaluation for, 468
 patient goals in, 468
 principles of, 464
 resources for, 472
 techniques for, 471
 vs. makeup artists, 467
- Cancer, of colon, in Birt-Hogg-Dube syndrome, 216
 of skin. See *Skin cancer*.
 of thyroid, in Gardner's syndrome, 54
- Candidiasis, in HIV infection, 234-235
- Cannulas, sizes of, for tumescent liposuction, 330
- Capsaicin, for psoriasis, 917
- Carbon dioxide lasers, in cosmetic dermatology, 448-449

- Carcinoma, basal cell, in nevoid basal cell carcinoma syndrome, 114
 increased risk of, therapy for psoriasis and, 860
 interferons for, 702-703
 colorectal, in Muir-Torre syndrome, 86
 hepatocellular, in HLA-linked hemochromatosis, 59
 in porphyrias. See *Porphyrias*.
 medullary thyroid, in Birt-Hogg-Dube syndrome, 215-216
 in multiple endocrine neoplasia 2/2A, 94
 in multiple endocrine neoplasia 2B/3, 101-102
 periampullary, in Gardner's syndrome, 54
 squamous cell, increased risk of, therapy for psoriasis and, 859-860
 interferons for, 703-704
- Cardiac fibromas, in nevoid basal cell carcinoma syndrome, 119
- Cardiac myxomas, in Carney complex, 22
- Cardiovascular abnormalities, in tuberous sclerosis complex, 154
- Cardiovascular disease, increased risk of, therapy for psoriasis and, 720
- Cardiovascular effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
- Carney complex, 19-26
 mucocutaneous stigmata of, 20-21
 noncutaneous features of, 22-24
 cardiac myxomas, 22
 myxoid mammary fibroadenomas, 23-24
 pituitary adenomas, 24
 primary pigmented nodular adrenal disease, 22-23
 psammomatous melanotic schwannomas, 24
 testicular large cell calcifying Sertoli cell tumors, 24
- Cataracts, juvenile posterior subcapsular, in neurofibromatosis, 108
 systemic glucocorticosteroids and, 932
- Caustic solutions, in sclerotherapy, for varicose and telangiectatic veins, 441-442
- Cellular effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
- Cellular radiation sensitivity, in nevoid basal cell carcinoma syndrome, 120
- Central nervous system, malignancies of, in Gardner's syndrome, 54
- Cervical dysplasia, human papillomavirus in, 567-568
- Chédiak-Higashi syndrome, malignancies associated with, 67-68
- Cheeks, microlipoinjection of autologous fat in, 344
- Chemical peels, for aging face, 255, 257
 complications of, 309-312
 procedural side effects, 309-310
 glycolic acid in, 285-307
 acid application in, 291, 293
 complications of, 294-295
 histology of, 295
 indications for, 286-289
 mechanism of action of, 285
 medications and combination therapies in, 290
 postoperative care for, 293-295
 prepeel planning in, 289-290
 results of, 295, 297
 skin preparation for, 290-293
 immediately prepeel, 291
 two to four weeks prior to peel, 290-291
 with other peeling agents, 295
- Jessner's-trichloroacetic acid in, medium-depth peels, 277-283
 complications of, 282-283
 method for, 277-282
 patient consultation for, 277-278
 postoperative care for, 281-282
 preoperative preparation for, 278-279
 results of, 282-283
- trichloroacetic acid and phenol in, 263-276
 classification of agents for, 263
 deep peels, 265-271
 complications of, 271
 informed consent for, 269
 intraoperative monitoring and anesthesia for, 269
 mixing and application of solution for, 269-270
 patient postoperative visits after, 270-271
 pretreatment of skin for, 269
 relative contraindications to, 268-269
 taping and postoperative care for, 270
 histology of, 274
 historical aspects of, 263
 medium-depth peels, 271-274
 patient selection for, 263-265
 superficial peels, 274
 vs. dermabrasion, 258
- Chemicals, exposure to, and skin cancer, 590
- Chemosis, blepharoplasty and, 419
- Chemotherapy, as contraindication to dermabrasion, 317
 vs. dermabrasion, 325-326
- Chemotherapy, for psoriasis, 5-fluorouracil, 885-887, 915
 hydroxyurea, 875, 885-886
 mechanism of action of, 876
 mechlorethamine, 887
 methotrexate. See *Methotrexate*.
 6-thioguanine, 875, 886
 thiotepe, 887
 topical methotrexate, 887
- Chondrosarcoma, in Maffucci's syndrome, 74
- Chromated glycerin, in sclerotherapy, for varicose and telangiectatic veins, 442
- Chromosome instability, in nevoid basal cell carcinoma syndrome, 120
- Chronic granulomatous disease, interferons for, 702
- Cigarette smoking, role of, in psoriasis, 641, 718
- Cirrhosis, methotrexate and, for psoriasis, 881, 919
- Cleft lip and palate, in nevoid basal cell carcinoma syndrome, 118
- Clobetasol propionate, for psoriasis, 810
- Clotrimazole, for candidiasis, in HIV infection, 234
- Cockayne's syndrome, vs. xeroderma pigmentosum, 194-195
- Collagen, autologous, microlipoinjection of. See *Microlipoinjection*.
- Colon, adenocarcinoma of, in Gardner's syndrome, 54
 cancer of, in Birt-Hogg-Dube syndrome, 216
 polyposis of, in Birt-Hogg-Dube syndrome, 215
- Colorectal carcinoma, in Muir-Torre syndrome, 86
- Complete blood count, to monitor methotrexate therapy, for psoriasis, 879
- Compression, after sclerotherapy, for varicose and telangiectatic veins, 442
- Condyloma acuminatum, in HIV infection, 233-234
 interferons for, 699-701
- Contact dermatitis, anthralin and, for psoriasis, 824
 occupational. See *Occupational contact dermatitis*.
 topical corticosteroids and, for psoriasis, 812
- Contact sensitization, in sunscreen intolerance, 473-475, 477-478
- Contact urticaria, in sunscreen intolerance, 478
- Contour defects, blepharoplasty and, 421-422
- Copper bromide lasers, in cosmetic dermatology, 451, 456

- Corneal irritation, blepharoplasty and, 419
- Corticosteroids, systemic. *See* Systemic corticosteroids.
- topical. *See* Topical corticosteroids.
- Cosmetic dermatology, blepharoplasty in. *See* Blepharoplasty.
- camouflage therapy in. *See* Camouflage therapy.
- chemical peels in. *See* Chemical peels.
- cosmetics in. *See* Cosmetics.
- dermabrasion in. *See* Dermabrasion.
- for aging face. *See* Aging face.
- hair transplantation in. *See* Hair transplantation.
- lasers in. *See* Lasers.
- microinjection of autologous collagen in. *See* Microlipoinjection.
- microlipoinjection of autologous fat in. *See* Microlipoinjection.
- sclerotherapy in. *See* Sclerotherapy.
- sunscreens intolerance in. *See* Sunscreen intolerance.
- tumescent liposuction in. *See* Tumescent liposuction.
- Cosmetics, in postsurgical patient, 461-465
- camouflage therapy in. *See* Camouflage therapy.
- eye cosmetics in, 463
- facial foundations in, 462
- lip cosmetics in, 463
- powders and blushers in, 463
- removal of, 463-464
- skin care and, 461-462
- incisional wounds, 461
- large surface area wounds, 461-462
- undercover foundations in, 463
- Cowden syndrome, 27-31
- breast lesions in, 28
- diagnosis of, 27
- eye lesions in, 29
- gastrointestinal lesions in, 29
- genitourinary tract abnormalities in, 29
- management of, 30-31
- mucocutaneous stigmata of, 27-28
- pathophysiology of, 30
- skeletal abnormalities in, 29
- thyroid gland lesions in, 28
- Cross-sensitization reactions, in sunscreen intolerance, 475-476
- Cryopeels, for aging face, 257
- Cushing's syndrome, in Carney complex, 22-23
- topical corticosteroids and, for psoriasis, 811
- Cutaneous effects, of systemic glucocorticosteroids. *See* Systemic glucocorticosteroids.
- Cutaneous malignant melanoma, 605-612
- genetic epidemiology of, 605-609
- candidate gene p16 in, 607
- chromosome 1p in, 606
- chromosome 9p in, 606-607
- complexities of, 607-609
- description, 605
- future studies in, 609
- principles of linkage analysis, 605-606
- public health issues in, 609-610
- education, 610
- screening and management, 609-610
- Cyclosporine, for erythrodermic psoriasis, 769
- for psoriasis, 743-744, 897-907, 917, 920
- dosage and schedule for, 899-900
- follow-up of, 905
- indications for, 903-905
- mechanism of action of, 897, 899
- pharmacokinetics of, 899
- pretherapy evaluation for, 904-905
- side effects of, 900-903
- with methotrexate, 884, 903-904
- with phototherapy, 871, 904
- for psoriatic arthritis, 791
- Cysts, epidermoid, in Gardner's syndrome, 51-52
- mesenteric, in nevroid basal cell carcinoma syndrome, 119
- renal, in tuberous sclerosis complex, 156
- Dardour flaps, in hair transplantation, 383
- Dental abnormalities, in Gardner's syndrome, 53
- Depigmentation, chemical peels and, 271
- Dermabrasion, 313-327
- adjunctive procedures with, 323-325
- anesthesia for, 320
- complications of, 322-323
- contraindications to, 317-318
- for acne scarring, 313-315
- for active acne, 315
- for aging face, 257-261
- vs. chemical peels, 258
- for rhytides, 315-316
- for tattoo removal, 316
- for vitiligo, 316
- indications for, 313
- instrumentation for, 319-320
- office and staffing considerations in, 320
- patient education and informed consent for, 318
- patient selection for, 313
- physician qualifications and technical skills for, 318
- postoperative care for, 321-322
- preoperative planning for, 318-319
- repeat, 326
- techniques for, 321
- vs. chemosurgery or laser surgery, 325-326
- Dermatitis, atopic. *See* Atopic dermatitis.
- occupational contact. *See* Occupational contact dermatitis.
- seborrheic, in HIV infection, 235-236
- Dermatoepidemiology, dermatologic health services research in, 689-695
- avoidance of bias in, 693-694
- data measurement in, 693
- data sources in, 693
- generalizability in, 694
- patient sample in, 693
- patient's perspective on, 692
- physician's perspective on, 690-692
- developing and measuring outcome, 690-692
- profiling types of care, 690
- research question in, 693
- society's perspective on, 692
- study design in, 693
- of acquired melanocytic nevi. *See* Acquired melanocytic nevi.
- of atopic dermatitis. *See* Atopic dermatitis.
- of cutaneous malignant melanoma. *See* Cutaneous malignant melanoma.
- of drug reactions. *See* Drug reactions.
- of epidermolysis bullosa. *See* Epidermolysis bullosa.
- of human papillomaviruses. *See* Human papillomaviruses.
- of Kaposi's sarcoma. *See* Kaposi's sarcoma.
- of leishmaniasis. *See* Leishmaniasis.
- of leprosy. *See* Leprosy.
- of Lyme disease. *See* Lyme disease.
- of measles. *See* Measles.
- of melanoma. *See* Melanoma.
- of occupational contact dermatitis. *See* Occupational contact dermatitis.

- Dermatoepidemiology (*Continued*)
 of psoriasis. See *Psoriasis*.
 of skin cancer. See *Skin cancer*.
 terminology in, 697-698
- Dermatophytosis, in HIV infection, 235
- Desmoid tumors, in Gardner's syndrome, 52
- Detergent solutions, in sclerotherapy, for varicose and telangiectatic veins, 440-441
- Diabetes mellitus, in Bloom's syndrome, 9
- Diepoxybutane test, for Fanconi anemia, 42
- Diet, role of, in psoriasis, 641-642, 718-719
 in skin cancer, 590-591
- Dihydrofolate reductase inhibitors, for psoriasis, with methotrexate, 885
- DNA repair, for Rothmund-Thomson syndrome, 148
- Doppler ultrasound, in physical examination, of varicose and telangiectatic veins, 435-437
- Drug reactions, cutaneous, **681-688**
 angioedema, 685-686
 rates of, 682-683
 serum sickness and serum sickness-like reactions, 685
 sources of information on, 681-682
 toxic epidermal necrolysis, 683-684
- Dry eye syndrome, blepharoplasty and, 422
- Duncan's disease, malignancies associated with, 69-70
- Duplex ultrasound, in physical examination, of varicose and telangiectatic veins, 439
- Dyskeratosis congenita, **33-39**
 clinical evaluation of, 37
 cutaneous stigmata in, 33-34
 malignancies associated with, 35-37
 management of, 37-38
 noncutaneous features of, 34-37
 hematologic, 35
 physical, 34-35
 vs. Fanconi anemia, 37
- Dysplastic nevi, and melanoma, screening for, 629
- Dystrophic nails, in dyskeratosis congenita, 34
- Ear abnormalities, in Beckwith-Wiedemann syndrome, 213
- Echymosis, blepharoplasty and, 419
- Ectropion, blepharoplasty and, 419, 422
- Edema, blepharoplasty and, 421
 systemic glucocorticosteroids and, 934
- Electrodesiccation, with dermabrasion, 325
- Elliot flaps, in hair transplantation, 382
- Enchondromas, in Maffucci's syndrome. See *Maffucci's syndrome*.
- Endocrine overactivity, in Carney complex. See *Carney complex*.
- Endothelial cells, in psoriasis, 732, 741-742
- Enthesopathy, in psoriatic arthritis, 782-783, 785, 789-790
- Entropion, blepharoplasty and, 422
- Epidermal atrophy, topical corticosteroids and, for psoriasis, 812
- Epidermodysplasia verruciformis, human papillomavirus in, 564
- Epidermoid cysts, in Gardner's syndrome, 51-52
- Epidermolysis bullosa, **659-670**
 and skin cancer, 666-667
 disease registries of, 663-664
 National Epidermolysis Bullosa Registry, 664-667
 examples of data from, 665-667
 epidemiology of, 659-663
 classification and subclassification in, 661
- clinical outcomes in, 662
 differential surveillance in, 660
 misclassification bias in, 660-661
 natural history in, 662
 observational or informational bias in, 661
 phenotypes and genotypes in, 662-663
 prevalence and incidence in, 662
 quality of laboratory tests in, 661-662
 selection bias in, 659-660
 socioeconomic impact in, 662
- Erythema, anthralin and, for psoriasis, 823-824
 blepharoplasty and, 419, 421
 chemical peels and, 311
 dermabrasion and, 322
- Erythrodermic psoriasis, 763-769
 clinical features of, 764
 histopathology of, 764, 768
 provocative factors in, 768
 treatment of, 768-769
 systemic retinoids in, 892-893
 with psoriasis vulgaris, 763
- Ethanolamine oleate, in sclerotherapy, for varicose and telangiectatic veins, 441
- Ethyl chloride, in anesthesia, for dermabrasion, 320
- Etretinate, for psoriasis. See *Systemic retinoids*.
- Excited skin syndrome, in patch testing, for sunscreen intolerance, 478
- Extender of Frechet, in hair transplantation, 384-385
- Eyelids, chemical peels of, Jessner's-trichloroacetic acid in, 281
- Face lift, as contraindication to chemical peels, for aging face, 269
- Facial angiofibromas, in tuberous sclerosis complex, 152
- Facial hemiopathy, microlipoinjection of autologous fat for, 345
- Familial atypical multiple mole melanoma syndrome, malignancies associated with, 216-218
- Familial melanoma. See *Cutaneous malignant melanoma*.
- Fanconi anemia, **41-49**
 bone marrow transplantation for, 46
 diepoxybutane test for, 42
 international registry of, patient features in, 42-46
 congenital malformations, 43-45
 hematologic abnormalities, 45-46
 molecular studies of, 46-47
 umbilical cord blood transplantation for, 46
 vs. dyskeratosis congenita, 37
- Fat, autologous, microlipoinjection of. See *Microlipoinjection*.
- Female sex hormones, role of, in skin cancer, 590
- Fetal effects, of systemic glucocorticosteroids, 935
- Fetal rhabdomyomas, in nevoid basal cell carcinoma syndrome, 120
- Fibrel. See *Microlipoinjection, of autologous collagen*.
- Fibroadenomas, myxoid mammary, in Carney complex, 23-24
- Fibroblasts, in psoriasis, 731-732
- Fibrofolliculomas, in Birt-Hogg-Dube syndrome, 215
- Fibromas, cardiac, in nevoid basal cell carcinoma syndrome, 119
- ovarian, in nevoid basal cell carcinoma syndrome, 119-120
- perifollicular, in Birt-Hogg-Dube syndrome, 215
- unusual, in tuberous sclerosis complex, 152
- Fibroplasia, impaired, systemic glucocorticosteroids and, 935
- Fibrotic diseases, interferons for, 707-708

- FK506, for psoriasis, 744, 917
for psoriatic arthritis, 791
Flaps, in hair transplantation. See *Hair transplantation*.
Flashlamp-pumped pulsed dye lasers, in cosmetic dermatology, 450-451, 456
5-Fluorouracil, for psoriasis, 886-887, 915
with methotrexate, 885
Follicular mucinosis, interferons for, 706
Foscarnet, for herpes simplex infection, in HIV infection, 232
Freckling, axillary, in neurofibromatosis, 106-107
Freons, in anesthesia, for dermabrasion, 320
Frequency-doubled Nd:YAG lasers, in cosmetic dermatology, 456
Fumaric acid esters, for psoriasis, 920
Fungal infections, in HIV infection, 234-235
- Gardner's syndrome, 51-56
cutaneous stigmata in, 51-52
evaluation, management, and follow-up of, 54-55
malignancies associated with, 54
noncutaneous features of, 52-54
Gastrointestinal effects, of systemic glucocorticosteroids.
See *Systemic glucocorticosteroids*.
Gastrointestinal ganglioneuromatosis, in multiple endocrine neoplasia 2B/3, 100
Gastrointestinal lesions, in Cowden syndrome, 29
Gastrointestinal malignancies, in Peutz-Jeghers syndrome, 129-131
Genital herpes simplex infection, interferons for, 705
Genital human papillomavirus. See *Human papillomaviruses*.
Genitourinary tract abnormalities, in Cowden syndrome, 29
Genodermatoses, ataxia-telangiectasia. See *Ataxia-telangiectasia*.
Beckwith-Wiedemann syndrome. See *Beckwith-Wiedemann syndrome*.
Birt-Hogg-Dube syndrome, 215-216
Bloom's syndrome. See *Bloom's syndrome*.
Carney complex. See *Carney complex*.
Cowden syndrome. See *Cowden syndrome*.
dyskeratosis congenita. See *Dyskeratosis congenita*.
familial atypical multiple mole melanoma syndrome, 216-218
Fanconi anemia. See *Fanconi anemia*.
Gardner's syndrome. See *Gardner's syndrome*.
hereditary tylosis, 218-219
HLA-linked hemochromatosis. See *HLA-linked hemochromatosis*.
immunodeficiency syndromes. See *Immunodeficiency syndromes*.
incontinentia pigmenti, 219-220
Maffucci's syndrome. See *Maffucci's syndrome*.
Muir-Torre syndrome. See *Muir-Torre syndrome*.
multiple endocrine neoplasia 2/2A. See *Multiple endocrine neoplasia 2/2A*.
multiple endocrine neoplasia 2B/3. See *Multiple endocrine neoplasia 2B/3*.
neurofibromatosis. See *Neurofibromatosis*.
nevoid basal cell carcinoma syndrome. See *Nevoid basal cell carcinoma syndrome*.
Peutz-Jeghers syndrome. See *Peutz-Jeghers syndrome*.
porphyrias. See *Porphyrias*.
Rothmund-Thomson syndrome. See *Rothmund-Thomson syndrome*.
supernumerary nipples, 220-226
tuberous sclerosis. See *Tuberous sclerosis complex*.
Werner's syndrome. See *Werner's syndrome*.
xeroderma pigmentosum. See *Xeroderma pigmentosum*.
Genomic instability, in Bloom's syndrome, 15-16
Giant cell astrocytomas, in tuberous sclerosis complex, 156, 160
Glabellar furrows, microlipoinjection of autologous fat for, 343-344
Glaucoma, systemic glucocorticosteroids and, 932-933
Gliomas, optic nerve, in neurofibromatosis, 108-109
Glucocorticosteroids, systemic. See *Systemic glucocorticosteroids*.
Glycolic acid, in chemical peels. See *Chemical peels*.
Goeckerman regimen, for psoriasis, 820-822
Grafts, in hair transplantation. See *Hair transplantation*.
island. See *Island grafts*.
Griseofulvin, for dermatophytosis, in HIV infection, 235
Growth factor therapy, for dyskeratosis congenita, 37
Growth retardation, systemic glucocorticosteroids and, 931-932
Guttate psoriasis, clinical features of, 751-752
histopathology of, 753
HLA markers in, 752-753
response to therapy in, 753, 755
Gynecologic effects, of systemic glucocorticosteroids.
See *Systemic glucocorticosteroids*.
- Hair transplantation, 363-387
grafting in, 365-377
avoiding compression on, 371
combination micrografting with strip harvesting in, 368, 370
grading of, 374
placing grafts in, 376-377
planning for session size in, 371-372
pre- and postoperative instructions in, 370-371
producing recipient site for, 376
removing epidermis in, 374-375
standard micrografting session in, 366
strip harvesting technique in, 372-375
hair-bearing flaps in, 380-385
Dardour flap, 383
Elliot flap, 382
extender of Frechet, 384-385
instrumentation advances in, 385
Juri flap, 381-382
Nataf flap, 382-383
newer flaps worldwide, 383-384
historical aspects of, 363
ideal candidates for, 363-365
recipient site for, 365
scalp reduction in, 377-380
bilateral lateral technique for, 380
stretch back and long-term benefits of, 378-379
Hamartomas, retinal, in tuberous sclerosis complex, 152, 154
Hamartomatous polyps, in Peutz-Jeghers syndrome, 128
Hands, microlipoinjection of autologous fat in, 345
papillomas of, 563
Hemangioma, interferons for, 706
Hematologic abnormalities, in dyskeratosis congenita, 35
in Fanconi anemia, 45-46
Hematologic effects, of systemic glucocorticosteroids.
See *Systemic glucocorticosteroids*.
Hematomas, blepharoplasty and, 422-423
Hemihypertrophy, in Beckwith-Wiedemann syndrome, 214
Hemochromatosis, HLA-linked. See *HLA-linked hemochromatosis*.

- Heparsol, in sclerotherapy, for varicose and telangiectatic veins, 441
- Hepatitis infections, as contraindication to dermabrasion, 317-318
- Hepatocellular carcinoma, in HLA-linked hemochromatosis, 59
- in porphyrias. See *Porphyrias*.
- Hereditary tylosis, malignancies associated with, 218-219
- Herpes simplex hepatitis, methotrexate and, for psoriasis, 882
- Herpes simplex infections, as contraindication to chemical peels, for aging face, 268
- as contraindication to dermabrasion, 317
- genital, interferons for, 705
- in chemical peels, 310
- in HIV infection, 232-233
- Herpes zoster, interferons for, 705-706
- methotrexate and, for psoriasis, 882
- HIV infection, as contraindication to dermabrasion, 317-318
- as contraindication to measles vaccination, 557
- skin diseases in, 231-238
- bacterial infections, 231-232
 - bacillary angiomatosis, 231-232
 - Staphylococcus aureus* infections, 231
 - syphilis, 232
 - papulosquamous diseases, 235-237
 - aphthous stomatitis, 237
 - generalized pruritus, 237
 - papular dermatoses, 236-237
 - psoriasis and Reiter's disease, 236, 719, 726
 - seborrheic dermatitis, 235-236
 - viral infections, 232-235
 - herpes simplex, 232-233
 - human papillomavirus, 233-234
 - molluscum contagiosum, 233
 - mucocutaneous fungal infections, 234-235
 - oral hairy leukoplakia, 233
 - varicella-zoster virus, 233
- with leprosy, 533
- with porphyrias, 139-140
- with psoriatic arthritis, 781, 789, 791
- HLA-linked hemochromatosis, 57-63
- diagnosis and treatment of, 60-62
- historical aspects of, 57-58
- incidence of, 57
- malignancies associated with, 59-60
- mucocutaneous stigmata of, 58-59
- noncutaneous features of, 59
- pathogenesis of, 58
- Hormones, female sex, role of, in skin cancer, 590
- Human immunodeficiency virus infection. See *HIV infection*.
- Human papillomaviruses, 561-574
- biologic characteristics of, affecting epidemiology, 562
- detection of, 561-562
- genital, 566-570
- frequency of, 566-567
 - in children, 568-570
 - natural history and relation to malignancy of, 567-568
- in epidermodysplasia verruciformis, 564
- in HIV infection, 233-234
- in immunocompetent patients, 564, 566
- in immunosuppressed patients, 564
- nongenital cutaneous, 562-564
- Hydroxyurea, for psoriasis, 875, 885-886
- for pustular psoriasis, 762
- Hyperglycemia, systemic glucocorticosteroids and, 933-934
- Hyperlipidemia, systemic glucocorticosteroids and, 934
- Hyperpigmentation, chemical peels and, 271, 294-295, 309
- dermabrasion and, 323
- Hypertension, cyclosporine and, for psoriasis, 902
- systemic glucocorticosteroids and, 934
- Hypertonic dextrose and saline, in sclerotherapy, for varicose and telangiectatic veins, 441
- Hypertonic saline, in sclerotherapy, for varicose and telangiectatic veins, 441
- Hypertrophic scarring, chemical peels and, 294, 311
- dermabrasion and, 323
- Hypoglycemia, in Beckwith-Wiedemann syndrome, 214
- Hypogonadism, in nevroid basal cell carcinoma syndrome, 118
- Hypomelanotic macules, in tuberous sclerosis complex, 151-152
- Hypopigmentation, chemical peels and, 271, 295, 309
- dermabrasion and, 323
- Hypothalamic-pituitary-adrenal axis, and systemic glucocorticosteroids, 927, 936-937
- Immune system, compromised, as contraindication to measles vaccination, 557
- Immunocompetent patients, human papillomavirus in, 564, 566
- Immunocompromised patients, human papillomavirus in, 564
- skin cancer in, 590
- Immunodeficiency, in ataxia-telangiectasia, 3
- in Bloom's syndrome, 9-10
- Immunodeficiency syndromes, 65-71
- Chédiak-Higashi syndrome, 67-68
 - panhypoglobulinemia syndromes, 65-67
 - Wiskott-Aldrich syndrome, 68-69
 - X-linked lymphoproliferative disorder, 69-70
- Immunologic effects, of PUVA therapy, for psoriasis, 858-859
- Immunomodulatory agents, for psoriasis, 920
- Immunosuppression, systemic glucocorticosteroids and, 935
- Immunotherapy, for psoriasis. See *Psoriasis*.
- Incontinentia pigmenti, malignancies associated with, 219-220
- Infections, bacterial, in Wiskott-Aldrich syndrome, 68
- chemical peels and, 271, 294, 310
 - in HIV infection. See *HIV infection*.
 - methotrexate and, for psoriasis, 882
 - role of, in psoriasis, 641, 718, 725-726, 741
- Infertility, methotrexate and, for psoriasis, 882
- Ingram regimen, for psoriasis, 824-825
- Insulin-like growth factor 2, in Beckwith-Wiedemann syndrome, 212
- Interferons, dermatologic uses of, 699-711
- FDA-approved, 699-702
 - AIDS-related Kaposi's sarcoma, 701
 - chronic granulomatous disease, 702
 - condyloma acuminatum, 699-701
 - for human papillomavirus infection, in HIV infection, 234
 - non-FDA-approved, 702-708
 - actinic keratosis and squamous cell carcinoma, 703-704
 - atopic dermatitis, 702
 - basal cell carcinoma, 702-703
 - Behçet's disease, 706
 - follicular mucinosis, 706
 - genital herpes simplex, 705

Interferons (*Continued*)

- hemangioma, 706
- herpes zoster, 705-706
- keratoacanthoma, 705
- lupus erythematosus, 706
- melanoma, 704-705
- mycosis fungoides, 705
- psoriatic arthritis, 706-707
- systemic sclerosis and fibrotic diseases, 707-708
- verruca vulgaris/bowenoid papulosis, 706
- Intraocular pressure, increase in, blepharoplasty and, 423
- Ionizing radiation, role of, in skin cancer, 590
- Iron overload. *See* HLA-linked hemochromatosis.
- Irritant solutions, in sclerotherapy, for varicose and telangiectatic veins, 441-442
- Island grafts, to close wound defects, 483-498
 - elliptical primary defect, 490, 492
 - irregular primary defect, 483-484, 487
 - named? geometric primary defect, 487, 490, 492
 - trapezoidal primary defect, 490
 - triangular primary defect, 487
 - unusual primary defect, 492, 498
- Isotretinoin, for psoriasis, with PUVA therapy, 871
 - prior use of, as contraindication to dermabrasion, 317
- Itraconazole, for candidiasis, in HIV infection, 235
- Jessner's-trichloroacetic acid, in chemical peels. *See* Chemical peels.
- Jordan light, in Goeckerman therapy, for psoriasis, 821
- Juri flaps, in hair transplantation, 381-382
- Juvenile posterior subcapsular cataracts, in neurofibromatosis, 108
- Kaposi's sarcoma, 575-582
 - AIDS-related, 575, 577-581
 - epidemiologic variables in, 578-580
 - clustering by person, place, and time, 579-580
 - person, 578-579
 - place, 579
 - time, 579
 - etiology of, 580-581
 - interferons for, 701
 - historical aspects of, 575
 - Karyotyping, of ataxia-telangiectasia, 3
 - Keloids, interferons for, 707-708
 - Keratinocytes, in psoriasis, 731, 740
 - Keratoacanthomas, in Muir-Torre syndrome, 81-82
 - interferons for, 705
 - Keratoconjunctivitis sicca, blepharoplasty and, 422
 - Keratocysts, odontogenic, in nevroid basal cell carcinoma syndrome, 115-116
 - Ketoconazole, for candidiasis, in HIV infection, 235
 - for dermatophytosis, in HIV infection, 235
 - Kidney abnormalities, in nevroid basal cell carcinoma syndrome, 118
 - Kidney disease, cyclosporine and, for psoriasis, 902-903
 - Koebner reaction, in psoriasis, 726-727
 - Krypton lasers, in cosmetic dermatology, 451, 456
 - Lagophthalmus, blepharoplasty and, 422
 - Laser surgery, vs. dermabrasion, 325-326
 - Lasers, in cosmetic dermatology, 447-460
 - alexandrite lasers, 455

- argon lasers, 449
- argon-pumped tunable dye lasers, 450
- carbon dioxide lasers, 448-449
- copper bromide lasers, 451
- for pigmented lesions, 455-456
- frequency-doubled Nd:YAG lasers, 456
- krypton lasers, 451
- Nd:YAG lasers, 454-455
- physics of, 447
- Q-switched lasers, 451, 453-455
- ruby lasers, 453-454
- tissue interaction with, 447-448
- visible light lasers, 449-451
- yellow light lasers, 449-451
- Leishmaniases, 505-523
 - clinical features of, 507-508
 - cutaneous, 507-508
 - visceral, 508
 - diagnosis of, 508-509
 - epidemiologic triangle in, 511-513
 - anthroponoses, 512
 - New World, 512
 - Old World, 512
 - reservoir hosts, 511
 - sand fly vector, 513
 - geographic distribution of, 510-511
 - incidence and prevalence of, 509-510
 - life cycle of, 505-506
 - modes of transmission in, 516-517
 - prevention and control of, 518
 - risk factors for, 513, 515-516
 - taxonomy of, 5-6
 - treatment of, 509
 - tropism in, 506-507
- Lentigines, in Carney complex, 20
- Leprosy, 525-536
 - classification of, 526
 - clinical features of, 525-528
 - detection rates in, 532-533
 - epidemiology of, 528-532
 - future trends in, 533-535
 - nerve damage in, 527-528
 - treatment of, 532
 - vaccination against, 533
- Leucovorin, with methotrexate, for psoriasis, 885
- Leucovorin rescue, for methotrexate overdose, in psoriasis, 883
- Leukopenia, methotrexate and, for psoriasis, 881
- Leukoplakia, in dyskeratosis congenita, 34
- Lichen amyloidosis, in multiple endocrine neoplasia 2/2A, 92
- Lipids, elevation of, systemic retinoids and, for psoriasis, 894
- Liposuction, tumescent. *See* Tumescent liposuction.
- Lips, microlipoinjection of autologous fat in, 344
 - upper, dermabrasion of, 259-261
- Lisch nodules, in neurofibromatosis, 108
- Liver biopsies, to monitor methotrexate therapy, for psoriasis, 880
- Liver disease, methotrexate and, for psoriasis, 881-882
 - systemic retinoids and, for psoriasis, 894
- Liver function tests, to monitor methotrexate therapy, for psoriasis, 879-880
- Lung disease, methotrexate and, for psoriatic arthritis, 790-791
- Lupus erythematosus, interferons for, 706
- Lupus profundus, microlipoinjection of autologous fat for, 344-345
- Lyme disease, 537-551
 - diagnosis of, 539

- Lyme disease (*Continued*)
 epidemiology of, 540-546
 alternate vectors, 542
 disease emergence, 545-546
 distribution of disease and its tick vectors, 540, 542
 risk factors, 546
 surveillance statistics, 543-545
 transmission of spirochete, 540
 vertebrate hosts, 542-543
 etiology of, 537-538
 host-parasite interaction in, 538-539
 prevention of, 546-547
 treatment of, 539-540
- Lymphoreticular malignancies, in Wiskott-Aldrich syndrome, 69
- Macroglossia, in Beckwith-Wiedemann syndrome, 212-213
- Maffucci's syndrome, 73-78
 malignancies associated with, 74
 mucocutaneous stigmata of, 73
 noncutaneous features of, 73-74
 work-up and follow-up of, 74-77
- Measles, 553-559
 clinical features of, 553-554
 diagnosis of, 554
 epidemiology of, 554-555
 prevention of, 555-556
 vaccination against, 556-557
 adverse reactions to, 557
 contraindications to, 557-558
 improvements in, 558
- Mechlorethamine, for psoriasis, 887
- Medullary thyroid carcinoma, in Birt-Hogg-Dube syndrome, 215-216
 in multiple endocrine neoplasia 2/2A, 94
 in multiple endocrine neoplasia 2B/3, 101-102
- Medulloblastoma, in nevoid basal cell carcinoma syndrome, 118-119
- Melanoma, cutaneous malignant. See *Cutaneous malignant melanoma*.
 in xeroderma pigmentosum, 188-189
 increased risk of, therapy for psoriasis and, 720
 interferons for, 704-705
 screening for, 623-634
 definitions and applications of, 624-625
 education and early detection programs in, 625-626
 international, 631-632
 in high-risk people, 629-630
 mass screening, 626-628
 educational effects of, 627-628
 risk profiles in, 627
 visual examination in, 626-627
 yield of, 626
 outcome measures in, 625
 professional education in, 630-631
 self-screening, 628-629
- Melolabial furrows, microlipoinjection of autologous fat for, 344
- Mesenteric cysts, in nevoid basal cell carcinoma syndrome, 119
- Metabolic effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
- Methotrexate, for erythrodermic psoriasis, 768
 for psoriasis, 743, 817-818, 875-890, 919
 contraindications to, 878
 current uses of, 877-878
 dosage and schedule for, 879
 historical aspects and efficacy of, 876-877
 in HIV infection, 236
 indications for, 877
 mechanism of action of, 876
 monitoring of, 879-880
 patient selection for, 878
 pharmacology of, 877
 pretherapy evaluation for, 878
 side effects of, 880-883
 antidote to, 883
 drug interactions, 882-883
 hematologic, 881
 hepatic, 881-882
 infectious, 882
 infertility, 882
 topical, 887, 915
 with cyclosporine, 884, 903-904
 with dihydrofolate reductase inhibitors, 885
 with 5-fluorouracil, 885
 with leucovorin, 885
 with phototherapy, 848, 869-870, 883-884
 with systemic retinoids, 884
 for psoriatic arthritis, 790
 for pustular psoriasis, 762
- 8-Methoxypsoralen. See *PUVA therapy*.
- Microlipoinjection, of autologous collagen, for dermal defects, 347-350
 complications of, 349
 Fibrel in, 251, 353-361
 adverse reactions to, 359
 contraindications to, 356
 Fibrel kit in, 355-356
 future uses of, 359-360
 historical aspects of, 353-354
 indications for, 356
 injection techniques for, 356-358
 mechanism of action of, 354-355
 results of, 358-359
 skin test procedure in, 356
 historical aspects of, 347-348
 longevity of, 349-350
 technique for, 348-349
 of autologous fat, for aging face, 251, 255
 for dermal defects, 339-347
 complications of, 345
 historical aspects of, 339
 indications for, 343-345
 longevity of, 345, 347
 microlipoextraction of fat in, 339-340
 reimplantation of fat in, 342-343
 treatment of collected fat in, 340
- Milia, blepharoplasty and, 421
 chemical peels and, 310
 dermabrasion and, 323
 in nevoid basal cell carcinoma syndrome, 114
- Moisturizers, for aging face, 248
- Molecular studies, of Fanconi anemia, 46-47
- Molluscum contagiosum, in HIV infection, 233
- Mometasone furoate, for psoriasis, 916
- Morphea, microlipoinjection of autologous fat for, 344-345
- Mucosal neuromas, in multiple endocrine neoplasia 2B/3, 99
- Muir-Torre syndrome, 79-89
 cutaneous stigmata in, 81-82
 historical aspects of, 79-81
 incidence of, 79
 malignancies associated with, 86
 noncutaneous features of, 82, 86
 work-up and follow-up of, 87

- Multiple endocrine neoplasia 2/2A, 91-97
 mucocutaneous stigmata of, 92
 noncutaneous features of, 92-95
- Multiple endocrine neoplasia 2B/3, 99-103
 diagnosis and screening of, 102-103
 malignancies associated with, 101-102
 mucocutaneous stigmata of, 99-100
 noncutaneous features of, 100-101
- Multiple hamartoma syndrome. See *Cowden syndrome*.
- Musculoskeletal abnormalities, in multiple endocrine neoplasia 2B/3, 100-101
- Musculoskeletal effects, of systemic glucocorticosteroids.
 See *Systemic glucocorticosteroids*.
 of systemic retinoids, for psoriasis, 894
- Mycophenolic acid, for psoriasis, 875-876
- Mycosis fungoides, interferons for, 705
- Myopathy, systemic glucocorticosteroids and, 932
- Myxomas, in Carney complex. See *Carney complex*.
- Nail disease, with psoriatic arthritis, 785-786
- Nails, dystrophic, in dyskeratosis congenita, 34
 psoriasis of, 772-773
- Nasolabial furrows, microlipoinjection of autologous fat for, 344
- Nataf flaps, in hair transplantation, 382-383
- Nd:YAG lasers, in cosmetic dermatology, 454-455
- Neoplastic effects, of PUVA therapy, for psoriasis, 859-860
- Nervous system effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
- Neurofibromas, in neurofibromatosis, 107-108
- Neurofibromatosis, 105-111
 malignancies associated with, 108-110
 optic nerve gliomas, 108-109
 peripheral nerve sheath tumors, 109
 pheochromocytoma, 110
 spinal tumors, 109
 vestibular schwannomas, 109
 mucocutaneous stigmata of, 105-108
 axillary freckling, 106-107
 café-au-lait macules, 105-106
 neurofibromas, 107-108
 noncutaneous features of, 108
 work-up and follow-up of, 110-111
- Neurologic abnormalities, in tuberous sclerosis complex, 156
 in xeroderma pigmentosum, 189-190
- Neuromas, mucosal, in multiple endocrine neoplasia 2B/3, 99
- Neurons, in psoriasis, 742
- Neuropsychiatric effects, of systemic glucocorticosteroids, 936
- Nevi, acquired melanocytic. See *Acquired melanocytic nevi*.
 benign pigmented, and melanoma, screening for, 629
 dysplastic, and melanoma, screening for, 629
- Nevoid basal cell carcinoma syndrome, 113-125
 basal cell carcinoma in, 114
 cardiac fibroma in, 119
 chromosome instability and cellular radiation sensitivity in, 120
 fetal rhabdomyoma in, 120
 general appearance of, 113-114
 heredity in, 120
 medulloblastoma in, 118-119
 mesenteric cysts in, 119
 milia in, 114
 musculoskeletal radiographic findings in, 116-118
 odontogenic keratocysts in, 115-116
 ovarian fibromas in, 119-120
 palmar and plantar pits in, 115
 Nevus flammeus, facial, in Beckwith-Wiedemann syndrome, 213-214
 Nitrogen mustard, for psoriasis, 887
 Nonmelanoma skin cancer, PUVA therapy and, for psoriasis, 859-860
 Nonsolar ultraviolet radiation, role of, in skin cancer, 589-590
 Nonsteroidal anti-inflammatory drugs, for psoriatic arthritis, 789-790
- Obesity, systemic glucocorticosteroids and, 934
- Obstetric effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
- Occupational contact dermatitis, 671-680
 epidemiology of, 671-673
 problems in assessing, 672-673
 etiology of, 677
 population at risk for, 675-677
 prevention of, 677-678
 prognosis for, 677
 public health issues in, 673-675
 United States Bureau of Labor Statistics data on, 673
 workers' compensation data on, 674-675
- Ocular abnormalities, in Cowden syndrome, 29
 in dyskeratosis congenita, 34
 in Gardner's syndrome, 53-54
 in multiple endocrine neoplasia 2B/3, 99-100
 in nevoid basal cell carcinoma syndrome, 118
 in Rothmund-Thomson syndrome, 146
 in tuberous sclerosis complex, 152, 154
- Ocular apraxia, in ataxia-telangiectasia, 2
- Odontogenic keratocysts, in nevoid basal cell carcinoma syndrome, 115-116
- Ophthalmologic effects, of PUVA therapy, for psoriasis, 858
 of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
 of systemic retinoids, for psoriasis, 895
- Optic nerve gliomas, in neurofibromatosis, 108-109
- Oral abnormalities, in dyskeratosis congenita, 34
 in Rothmund-Thomson syndrome, 145
- Oral cavity, papillomas of, 564
- Oral commissures, microlipoinjection of autologous fat for, 344
- Oral hairy leukoplakia, in HIV infection, 233
- Osmotic solutions, in sclerotherapy, for varicose and telangiectatic veins, 441
- Osteomas, in Gardner's syndrome, 52-53, 54-55
- Osteonecrosis, systemic glucocorticosteroids and, 930-931
- Osteoporosis, systemic glucocorticosteroids and, 929-930
- Osteosarcoma, in Rothmund-Thomson syndrome, 147
- Ovarian fibromas, in nevoid basal cell carcinoma syndrome, 119-120
- Ovarian tumors, in Peutz-Jeghers syndrome, 130
- Palmar and plantar pits, in nevoid basal cell carcinoma syndrome, 115
- Palmoplantar psoriasis, 773-775
 differential diagnosis of, 773
 diseases associated with, 774

- Palmoplantar psoriasis** (*Continued*)
 etiology of, 773
 histopathology of, 774
 treatment of, 774-775
 with psoriasis, 774
- Pancytopenia, methotrexate and, for psoriasis**, 881
- Panhypoglobulinemia syndromes, malignancies associated with**, 65-67
- Papular dermatoses, in HIV infection**, 236-237
- Papulosquamous diseases, in HIV infection. See HIV infection.**
- Patch testing, for sunscreen intolerance**, 471-472
- Pentavalent antimonials, for leishmaniasis**, 509
- Peptic ulcer disease, systemic glucocorticosteroids and**, 933
- Periapillary carcinoma, in Gardner's syndrome**, 54
- Perifollicular fibromas, in Birt-Hogg-Dube syndrome**, 215
- Peripheral nerve sheath tumors, in neurofibromatosis**, 109
- Perthes' test, modified, in physical examination of varicose and telangiectatic veins**, 434-435
- Peutz-Jeghers syndrome**, 127-133
 clinical course of, 128-129
 malignancies associated with, 129-130
 mucocutaneous stigmata of, 127-128
 noncutaneous features of, 128
 work-up and follow-up of, 130-131
- Phenol, in chemical peels. See Chemical peels.**
- Phochromocytoma, in multiple endocrine neoplasia 2B/3**, 102
 in neurofibromatosis, 110
- Phlebotomy therapy, for HLA-linked hemochromatosis**, 62
 for porphyrias, 141
- Photoaging. See Aging face.**
- Photocontact sensitization, in sunscreen intolerance**, 473-475, 477-478
- Photodermatoses, sunscreen intolerance in**, 476-477
- Photoplethysmography, in physical examination of varicose and telangiectatic veins**, 437, 439
- Phototesting, for Rothmund-Thomson syndrome**, 147-148
 for sunscreen intolerance, 477-478
- Phototherapy. See also PUVA therapy; UVB therapy.**
 for erythrodermic psoriasis, 769
 for papular dermatoses, in HIV infection, 236-237
 for psoriasis, 841-849, 917-919
 electromagnetic spectrum of, 842
 erythemogenic vs. suberythemogenic, 844
 for maintenance therapy, 845
 frequency of, 844
 home administration of, 847
 in HIV infection, 236
 indications for, 845
 photobiologic effects of, 842
 PUVA plus UVB therapy, 848
 side effects of, 845-847
 tars vs. emollients in, 843-844
 treatment schedules for, 843
 ultraviolet irradiators in, 842-843
 vs. tars, 821-822
 with anthralin, 827-829, 869
 with calcipotriol, 836-837, 848, 918
 with cyclosporine, 871, 904
 with methotrexate, 848, 869-870, 883-884
 with systemic retinoids, 848, 870-871, 893-894, 918
 with topical corticosteroids, 810, 847-848, 868-869
 for pustular psoriasis, 762-763
- Pigmentation, dark, as contraindication to dermabrasion**, 318
 disturbances of, chemical peels and, 271, 294-295, 309, 311
 dermabrasion and, 323
 spotty, in Carney complex. *See Carney complex.*
- Pigmented lesions, removal of, lasers in**, 455-456
- Pituitary adenomas, in Carney complex**, 24
- Plaque psoriasis, clinical features of**, 751-752
 histopathology of, 753
 HLA markers in, 752-753
 response to therapy in, 753, 755
 systemic retinoids for, 893
- Podophyllin, for human papillomavirus infection, in HIV infection**, 233-234
- Polidocanol, in sclerotherapy, for varicose and telangiectatic veins**, 440
- Polyiodide iodine, in sclerotherapy, for varicose and telangiectatic veins**, 441-442
- Polyposis, of colon, in Birt-Hogg-Dube syndrome**, 215
- Polyps, adenomatous colon, in Gardner's syndrome**, 54, 55
 hamartomatous, in Peutz-Jeghers syndrome, 128
- Porphyrias**, 135-142
 cutaneous stigmata of, 137-138
 differential diagnosis of, 140
 evaluation of, 140
 liver involvement in, 138-139
 noncutaneous features of, 139
 treatment of, 140-141
- Post-kala azar leishmaniasis, clinical features of**, 507-508
- Pregnancy, as contraindication to measles vaccination**, 557
- Proptosis, blepharoplasty and**, 419
- Propylthiouracil, for psoriasis**, 917
- Pruritus, in HIV infection**, 237
 PUVA therapy and, for psoriasis, 858
- Psammomatous melanotic schwannomas, in Carney complex**, 24
- Pseudotumor cerebri, systemic glucocorticosteroids and**, 936
- Psoriasis**, 635-647
 clinical course of, predicting and modifying, 642-644
 diseases associated with, 719-721
 epidemiology of, 717-722
 age effect in, 636-637
 disease occurrence in, 636
 genetic, 637-639, 717-718
 nongenetic host and environmental factors in, 639-642
 alcohol, 639-641, 718, 796
 diet, 641-642, 718-719
 drugs, 641, 719
 infections, 641, 718, 725-726, 741
 smoking, 641, 718
 stress, 641
 trauma, 641
 erythrodermic. *See Erythrodermic psoriasis.*
 guttate. *See Guttate psoriasis.*
 immunopathogenesis of, 739-742
 antigen-presenting cells in, 739-740
 endothelial cells in, 741-742
 keratinocytes in, 740
 neurons in, 742
 T-lymphocytes in, 740-741
 in HIV infection, 236
 in problem sites, 771-777
 acrodermatitis continua, 775
 nails, 772-773
 palmoplantar. *See Palmoplantar psoriasis.*
 scalp, 771-772

Psoriasis (*Continued*)

- natural history and prognosis of, 642-643
- pathogenesis of, 723-737
 - compartmental localization of cellular markers in, 729-732
 - genetics in, 723-724
 - in involved and uninvolved skin, 728-729
 - Koebner reaction in, 726-727
 - trigger factors in, 725-726
- plaque. *See* *Plaque psoriasis*.
- prevalence of, 717
- psychological aspects of, 793-804
 - behavioral techniques, 801
 - depression, 795-796
 - doctor-patient relationship, 799-800
 - group therapy, 800-801
 - impact of disease, 793-795
 - individual psychotherapy, 800
 - patient education, 799
 - stress, 796-799
- pustular. *See* *Pustular psoriasis*.
- risk factors for, 718-719
- treatment of, 643-644, 727-728
 - and increased risk of cancer, 719-720
 - anthralin in. *See* *Anthralin*.
 - antibiotics in. *See* *Antibiotics*.
 - calcipotriol in. *See* *Calcipotriol*.
 - chemotherapy in. *See* *Chemotherapy*.
 - cyclosporine in. *See* *Cyclosporine*.
 - future of, 915-923
 - advances in phototherapy, 917-919
 - new systemic therapies, 919-920
 - new topical therapies, 915-917
 - immunotherapy in, 742-745
 - biologic response modifiers, 745
 - exogenous immunomodulation, 742-744
 - highly specific, 744-745
 - methotrexate in. *See* *Methotrexate*.
 - phototherapy in. *See* *Phototherapy*.
 - PUVA therapy in. *See* *PUVA therapy*.
 - systemic retinoids in. *See* *Systemic retinoids*.
 - tars in. *See* *Tars*.
 - topical corticosteroids in. *See* *Topical corticosteroids*.
 - UVB therapy in. *See* *UVB therapy*.
- Psoriasis vulgaris, with erythrodermic psoriasis, 763
 - with pustular psoriasis, 757
- Psoriatic arthritis, 719, 725, 779-792
 - clinical features of, 783-786
 - joint disease, 784-786
 - onset, 783-784
 - skin disease, 784
 - course and prognosis of, 787
 - diagnosis of, 787-789
 - differential diagnosis of, 788-789
 - epidemiology of, 643, 779-780
 - etiology and pathogenesis of, 780-782
 - environmental factors in, 781-782
 - gene identification in, 780-781
 - genetic factors in, 780
 - HIV infection in, 781
 - immunogenetic factors in, 781
 - immunologic mechanisms in, 783
 - interferons for, 706-707
 - laboratory findings in, 786
 - pathology of, 782-783
 - pustulosis palmaris and plantaris and SAPHO with, 786
 - radiographic features of, 786-787
 - treatment of, 789-791
- Psychiatric problems, as contraindication to dermabrasion, 318
- Ptoxis, blepharoplasty and, 422
- Pulmonary abnormalities, in tuberous sclerosis complex, 156
- Punch elevation, with dermabrasion, 323
- Punch excision, and full-thickness graft replacement, with dermabrasion, 323, 325
- Pustular psoriasis, 757-763
 - clinical features of, 757, 759
 - histopathology of, 759, 761
 - provocative factors in, 761-762
 - treatment of, 762-763
 - systemic retinoids in, 892
 - with psoriasis vulgaris, 757
- Pustulosis palmaris and plantaris, with psoriatic arthritis, 786
- PUVA therapy. *See also* *Phototherapy*.
 - for erythrodermic psoriasis, 769
 - for palmoplantar psoriasis, 774-775
 - for psoriasis, 643-644, 828-829, 851-866, 917-918
 - and increased risk of cancer, 720
 - choice of drug in, 852-853
 - choice of radiation in, 853
 - histologic changes in, 860-863
 - historical aspects of, 851
 - modifications of, 867-873
 - current status of, 871
 - with anthralin, 869
 - with calcipotriol, 869
 - with cyclosporine, 871
 - with methotrexate, 869-870
 - with systemic retinoids, 870-871
 - with topical corticosteroids, 868-869
 - with UVB therapy, 870
 - side effects of, 857-860
 - immunologic, 858-859
 - neoplastic, 859-860
 - ophthalmologic, 858
 - technique for, 853-856
 - topical, 856-857
 - with calcipotriol, 837, 918
 - with methotrexate, 884
 - with systemic retinoids, 918
 - for pustular psoriasis, 763
 - role of, in skin cancer, 590
- Q-switched lasers, in cosmetic dermatology, 451, 453-455
- Radiation, ionizing, role of, in skin cancer, 590
- Radiodermatitis, as contraindication to dermabrasion, 317
- Radiosensitivity assays, of ataxia-telangiectasia, 4-5
- Rapamycin, for psoriasis, 744
- Rasmussen syndrome, basal cell carcinoma in, 121
- Reiter's disease, in HIV infection, 236
- Reiter's syndrome, vs. psoriatic arthritis, 788-789
- Renal abnormalities, in supernumerary nipples, 222
 - in tuberous sclerosis complex, 154, 156
- Renal transplant patients, human papillomavirus in, 564
- Respiratory papillomatosis, clinical features of, 563-564
- Retinal damage, blepharoplasty and, 423, 427
- Retinal hamartomas, in tuberous sclerosis complex, 152, 154
- Retinoic acid, to pretreat face, for chemical peels, 269
- Retinoids, for xeroderma pigmentosum, 199
 - systemic. *See* *Systemic retinoids*.

- Rhabdomyomas, cardiac, in tuberous sclerosis complex, 154
 fetal, in nevoid basal cell carcinoma syndrome, 120
 Rheumatoid arthritis, vs. psoriatic arthritis, 788
 Rheumatoid factor, in psoriatic arthritis, 788
 Rhytides, dermabrasion for, 315-316
 Rombo syndrome, basal cell carcinoma in, 121
 Rothmund-Thomson syndrome, 143-150
 age of onset of, 144
 differential diagnosis of, 145
 etiology of, 148
 histopathology of, 144-145
 malignancies associated with, 147-148
 management of, 148-149
 mucocutaneous stigmata of, 143-145
 noncutaneous features of, 145-147
 genetics in, 145-146
 growth and development, 146-147
 ocular abnormalities, 146
 skeletal abnormalities, 146
 Ruby lasers, in cosmetic dermatology, 453-454, 456
- SAPHO syndrome, with psoriatic arthritis, 786
 Scabies, in HIV infection, 235
 Scalp, psoriasis of, 771-772
 Scalp reduction, in hair transplantation. *See Hair transplantation.*
 Scarabrasion, with dermabrasion, 325
 Scarlet fever, and psoriasis, 719
 Scarring, acne, dermabrasion for, 313-315
 hypertrophic, chemical peels and, 271, 294, 311
 dermabrasion and, 323
 microlipoinjection of Fibrel for, 357-358
 Schwannomas, in Carney complex. *See Carney complex.*
 vestibular, in neurofibromatosis, 109
 Scleral show, blepharoplasty and, 422
 Sclerotherapy, for varicose and telangiectatic veins, 431-445
 compression following, 442
 historical aspects of, 431
 patient evaluation for, 431-439
 continuous wave Doppler ultrasound in, 435-437
 duplex ultrasound in, 439
 history in, 432
 photoplethysmography in, 437, 439
 physical examination in, 432, 434-435
 solutions for, 439-442
 detergent, 440-441
 irritant or caustic, 441-442
 osmotic, 441
 Sebaceous gland tumors, in Muir-Torre syndrome, 81-82
 Seborrheic dermatitis, in HIV infection, 235-236
 Sedation, in tumescent liposuction, 337
 Seizures, in tuberous sclerosis complex, 156
 Serum alphafetoprotein, in ataxia-telangiectasia, 3
 Serum sickness reactions, drug-induced, 685
 Shagreen patch, in tuberous sclerosis complex, 152
 Sipple syndrome. *See Multiple endocrine neoplasia 2/2A.*
 Skeletal abnormalities, in Cowden syndrome, 29
 in dyskeratosis congenita, 35
 in Rothmund-Thomson syndrome, 146
 Skin cancer, 583-594
 analytic epidemiology of, 586-591
 association with cutaneous sun sensitivity, 586-587
 association with personal sun exposure, 588-589
 pattern of exposure, 589
 quantitative relationship to sun exposure, 589
 burns, trauma, and ulceration and, 591
 chemical exposure and, 590
 descriptive epidemiology of, 583-586
 anatomic site distribution, 586
 and sun exposure, 586
 incidence measurement, 583-584
 incidence patterns, 584-585
 mortality measurement, 584
 time trends in incidence, 585-586
 diet and, 590-591
 epidermolysis bullosa and, 666-667
 female sex hormones and, 590
 immune suppression and, 590
 in Rothmund-Thomson syndrome, 147
 in xeroderma pigmentosum, 188-189
 increased risk of, therapy for psoriasis and, 720, 859-860
 ionizing radiation and, 590
 nonsolar ultraviolet radiation and, 589-590
 prevention of, behavioral changes in, 613-622
 appearance interventions for, 616
 interventions for, 614-615
 in children and adolescents, 615-616
 stage-based, 617-618
 stage-based sun exposure, 618-619
 need for, 613-614
 public knowledge, attitudes, and behavior in, 614
 stage model of, 616-617
 public health issues in, 591-592
 PUVA therapy and, 590
 Skin diseases, in HIV infection. *See HIV infection.*
 Skin refrigerants, in anesthesia, for dermabrasion, 320
 Smoking, role of, in psoriasis, 641, 718
 Sodium morrhuate, in sclerotherapy, for varicose and telangiectatic veins, 441
 Soft tissue augmentation, for aging face. *See Microlipoinjection.*
 Sotradecol, in sclerotherapy, for varicose and telangiectatic veins, 440-441
 Spinal tumors, in neurofibromatosis, 109
 Spotty pigmentation, in Carney complex. *See Carney complex.*
 Squamous cell carcinoma, in Rothmund-Thomson syndrome, 147
 increased risk of, therapy for psoriasis and, 720, 859-860
 interferons for, 703-704
 Staphylococcus aureus infections, in HIV infection, 231
 Stevens-Johnson syndrome, drug-induced, 683-684
 Streptococcal infections, role of, in psoriasis, 718, 725-726, 741
 Stretch back, in scalp reduction, in hair transplantation, 378-379
 Subcision, with dermabrasion, 325
 Sulfapyridine, for pustular psoriasis, 762
 Sulfasalazine, for psoriasis, 912
 for psoriatic arthritis, 790
 Sunscreen intolerance, 473-481
 contact and photocontact sensitization in, 473-475, 477-478
 cross-sensitization reactions in, 475-476
 in photodermatoses, 476-477
 in United States, 477
 patch and photopatch testing in, 477-478
 Sunscreens, for aging face, 248
 Supernumerary nipples, malignancies associated with, 220-226
 Synovitis, in psoriatic arthritis, 782
 Syphilis, in HIV infection, 232
 Systemic corticosteroids, for erythrodermic psoriasis, 768

Systemic corticosteroids (*Continued*)

- for psoriatic arthritis, 790
- for pustular psoriasis, 762
- prior treatment with, and pustular psoriasis, 761-762
- Systemic glucocorticosteroids, for psoriasis, 742-744
- hypothalamic-pituitary-adrenal axis in, 927
- indications for, 927-929
- minimizing complications of, 925-939
- pharmacology of, 925-927
- side effects of, 929-937
 - cardiovascular, 934
 - atherosclerosis, 934
 - edema, 934
 - hypertension, 934
 - cutaneous, 936
 - gastrointestinal, 933
 - nausea and vomiting, 933
 - peptic ulcer disease, 933
 - hematologic and cellular, 935
 - blood cell effects, 935
 - immunosuppression, 935
 - impaired fibroplasia, 935
 - hypothalamic-pituitary-adrenal axis suppression, 936-937
 - metabolic, 933-934
 - hyperglycemia, 933-934
 - hyperlipidemia, 934
 - obesity, 934
 - musculoskeletal, 929-932
 - growth retardation, 931-932
 - muscle effects, 932
 - osteonecrosis, 930-931
 - osteoporosis, 929-930
 - nervous system, 936
 - neuropsychiatric effects, 936
 - pseudotumor cerebri, 936
 - obstetric and gynecologic, 934-935
 - amenorrhea, 934-935
 - fetal effects, 935
 - ophthalmologic, 932-933
 - cataracts, 932
 - glaucoma, 932-933
- Systemic retinoids, for erythrodermic psoriasis, 768-769
 - for palmoplantar psoriasis, 775
 - for psoriasis, 743, 891-896, 916, 919-920
 - dosage and schedule for, 892-893
 - mechanism of action of, 891-892
 - monitoring and follow-up of, 895
 - side effects of, 894-895
 - with methotrexate, 884
 - with phototherapy, 848, 870-871, 893-894, 918
 - for psoriatic arthritis, 791
 - for pustular psoriasis, 762
- Systemic sclerosis, interferons for, 707-708

Tachyphylaxis, topical corticosteroids and, for psoriasis, 812-813

- Tars, for psoriasis, 818-822
 - as monotherapy, 819-820
 - in Goeckerman regimen, 820-822
 - mechanisms of action of, 819
 - pharmacologic variability of, 818-819
 - vs. phototherapy, 821-822
 - with phototherapy, 843-844

Tattoos, removal of, dermabrasion in, 316

lasers in. *See Lasers.*

Telangiectatic veins, sclerotherapy for. *See Sclerotherapy.*

Tenosynovitis, in psoriatic arthritis, 785

Terbinafine, for dermatophytosis, in HIV infection, 235

Testicular large cell calcifying Sertoli cell tumors, in

Carney complex, 24

Thalassemia, malignancies associated with, 60

6-Thioguanine, for psoriasis, 875, 886

for pustular psoriasis, 763

Thiotepa, for psoriasis, 887

Thromboembolic disease, increased risk of, therapy for psoriasis and, 720

Thyroid cancer, in Gardner's syndrome, 54

Thyroid gland lesions, in Cowden syndrome, 28

T-lymphocytes, in psoriasis, 740-741

Topical corticosteroids, for erythrodermic psoriasis, 768

for psoriasis, 805-815, 916-917

in maintenance treatment, 809-810

mechanism of action of, 806-807

of scalp, 771-772

pharmacology of, 807-808

physiology of, 805-806

potent preparations of, 808-809

side effects of, 810-813

cutaneous, 811-813

systemic, 811

with phototherapy, 810, 847-848, 868-869

for pustular psoriasis, 762

prior treatment with, and pustular psoriasis, 761-762

Tourniquets, in physical examination, of varicose and telangiectatic veins, 434

Toxic epidermal necrolysis, drug-induced, 683-684

Transferrin saturation, measurement of, in HLA-linked hemochromatosis, 61

Transfusions, blood, and leishmaniasis, 516-517

Transplantation, hair. *See Hair transplantation.*

Tretinoin, to pretreat face, for dermabrasion, 319

topical, for aging face, 249, 251

Trichloroacetic acid, in chemical peels. *See Chemical peels.*

Trichodyscomas, in Birt-Hogg-Dube syndrome, 215

Trichothiodystrophy, vs. xeroderma pigmentosum, 195

Tuberous sclerosis complex, 151-161

cardiovascular complications of, 154

cutaneous features of, 151-152

diagnosis of, 160

genetics of, 151

neurologic features of, 156, 160

ophthalmologic findings in, 152, 154

pulmonary complications of, 156

renal complications of, 154, 156

Tumescent liposuction, 329-338

anesthesia for, 329-330

complications of, 337

diet after, 336

healing process in, 336-337

immediate postoperative recovery in, 330-331

physical activity after, 336

postoperative compression requirements in, 331

postoperative drainage in, 333-335

absorbent dressings for, 335-336

technique for, 330

Tumescent Liposuction Garments in, 331-333

application of, 332-333

duration of, 333

laundering of, 333

removal of, 333

wound care and bathing after, 336

written aftercare instructions in, 331

Tumescent Liposuction Garments. *See Tumescent liposuction.*

Tumors, desmoid, in Gardner's syndrome, 52

ovarian, in Peutz-Jeghers syndrome, 130

Tumors (*Continued*)

- peripheral nerve sheath, in neurofibromatosis, 109
- sebaceous gland, in Muir-Torre syndrome, 81-82
- spinal, in neurofibromatosis, 109
- testicular large cell calcifying Sertoli cell, in Carney complex, 24
- Turcot's syndrome. See *Gardner's syndrome*.
- Tylosis, hereditary, malignancies associated with, 218-219

Ulceration, role of, in skin cancer, 591

Ultrasound, in physical examination, of varicose and telangiectatic veins, 435-437, 439

Ultraviolet radiation, nonsolar, role of, in skin cancer, 589-590

Umbilical cord blood transplantation, for Fanconi anemia, 46

Ungual fibromas, in tuberous sclerosis complex, 152

Upper lips, dermabrasion of, 259-261

UVB therapy. See also *Phototherapy*.

for erythrodermic psoriasis, 769

for psoriasis, 827-828, 917

vs. tars, 821-822

with methotrexate, 883-884

with PUVA therapy, 870

Varicella-zoster virus, in HIV infection, 233

Varicose veins, sclerotherapy for. See *Sclerotherapy*.

Vascular lesions, removal of, lasers in. See *Lasers*.

Verruca vulgaris, interferons for, 706

Vestibular schwannomas, in neurofibromatosis, 109

Viral infections, chemical peels and, 310

in HIV infection. See *HIV infection*.

Vitamin A and D derivatives, for psoriasis, 728

Vitamin D₃ analogues, for psoriasis. See *Calcipotriol*.

Vitiligo, dermabrasion for, 316

Werner's syndrome, 163-168

- cutaneous features of, 164
- historical aspects of, 163-164
- malignancies associated with, 164, 166-167
- work-up for, 167

Wiskott-Aldrich syndrome, malignancies associated with, 68-69

Wound defects, closure of, island grafts in. See *Island grafts*.

Xeroderma pigmentosum, 169-209

biochemical and immunologic deficiencies in, 187

clinical features of, 187-190

complementation group A, 190-191

complementation group B, 191-192

complementation group C, 192

complementation group D, 192-193

complementation group E, 193

complementation group F, 193

complementation group G, 193-194

diagnosis of, 197-198

DNA repair genes in, 195-199

effects of ultraviolet rays in human tissues, 170

responses to, 170-187

cellular sensitivity to ultraviolet radiation, 181

complementation group analysis, 179, 181

host-cell reactivation studies, 181, 183

mutagenesis, 183

nonhuman eukaryotic nucleotide excision repair systems, 184, 186-187

other DNA repair systems, 173

repair of altered bases: FAPY protein, 170

repair of pyrimidine dimers and bulky adducts, 171-173

specificity of repair defect, 176, 179

studies in cell-free systems, 183-184

unscheduled DNA synthesis, 173-174, 176

variant complementation group, 181

information resources for, 199

management of, 198-199

variant complementation group, 194-195

X-linked lymphoproliferative disorder, malignancies associated with, 69-70

Yellow light lasers, in cosmetic dermatology, 449-451

Zidovudine, for psoriasis, in HIV infection, 236